Neuphoria Therapeutics (NEUP) Current Leases (2023 - 2025)

Neuphoria Therapeutics (NEUP) has reported Current Leases for 3 consecutive years, with $85210.0 the latest figure, recorded in Q3 2025.

• On a quarterly basis, Current Leases fell 34.39% year-over-year to $85210.0 in Q3 2025; TTM through Sep 2025 was $85210.0, a 34.39% decrease from a year earlier, with the FY2025 full-year figure at $116314.0, down 4.65% from the prior year.
• Current Leases was $85210.0 for Q3 2025 at Neuphoria Therapeutics, down from $116314.0 in the prior quarter.
• Over five years, Current Leases peaked at $129881.0 in Q3 2024 and troughed at $85210.0 in Q3 2025.
• A 3-year average of $115365.0 and a median of $118492.0 in 2024 frame the typical range for Current Leases.
• Across the five-year window, Current Leases grew 7.07% in 2024 and sank 34.39% in 2025, its largest moves.
• Over 3 years, Current Leases stood at $113930.0 in 2023, then increased by 4.0% to $118492.0 in 2024, then dropped by 28.09% to $85210.0 in 2025.
• The last three Current Leases figures came in at $85210.0 (Q3 2025), $116314.0 (Q2 2025), and $121738.0 (Q1 2025), per Business Quant data.